Compare · AGL vs FMS
AGL vs FMS
Side-by-side comparison of agilon health inc. (AGL) and Fresenius Medical Care AG (FMS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AGL and FMS operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- FMS is the larger of the two at $12.31B, about 7.6x AGL ($1.62B).
- Over the past year, AGL is up 68.6% and FMS is down 23.1% - AGL leads by 91.7 points.
- AGL has been more active in the news (10 items in the past 4 weeks vs 9 for FMS).
- AGL has more recent analyst coverage (25 ratings vs 21 for FMS).
- Company
- agilon health inc.
- Fresenius Medical Care AG
- Price
- $96.31+1.01%
- $22.02+0.41%
- Market cap
- $1.62B
- $12.31B
- 1M return
- +246.69%
- +4.78%
- 1Y return
- +68.58%
- -23.15%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NYSE
- NYSE
- IPO
- 2021
- News (4w)
- 10
- 9
- Recent ratings
- 25
- 21
agilon health inc.
agilon health, inc. offers healthcare services for seniors through primary care physicians in the communities of the United States. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. The company was founded in 2016 and is based in Long Beach, California.
Fresenius Medical Care AG
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2020, it operated 4,092 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Latest AGL
- Chief Legal Officer Zamore Denise covered exercise/tax liability with 485 shares, decreasing direct ownership by 0.73% to 66,112 units (SEC Form 4) (tax liability)
- Director Wulf John William was granted 2,133 shares, increasing direct ownership by 15% to 16,765 units (SEC Form 4)
- Director Williams Ronald A was granted 2,133 shares, increasing direct ownership by 1% to 149,141 units (SEC Form 4)
- Director Mcloughlin Karen was granted 2,133 shares, increasing direct ownership by 35% to 8,207 units (SEC Form 4)
- Director Mckenzie Diana was granted 2,133 shares, increasing direct ownership by 39% to 7,633 units (SEC Form 4)
- Director Mansukani Sharad was granted 2,133 shares, increasing direct ownership by 4% to 56,242 units (SEC Form 4)
- Director Battaglia Silvana was granted 2,133 shares, increasing direct ownership by 37% to 7,926 units (SEC Form 4)
- agilon health inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Chief Accounting Officer Gertsch Timothy covered exercise/tax liability with 8 shares, decreasing direct ownership by 0.06% to 14,169 units (SEC Form 4) (for withholding tax)
- agilon health upgraded by Barclays with a new price target
Latest FMS
- Fresenius Medical Care launches kinexus worldwide, a unified digital platform to support home dialysis
- SEC Form 6-K filed by Fresenius Medical Care AG
- Fresenius Medical Care launches first tranche of its share buyback program of up to EUR 600 million
- SEC Form SD filed by Fresenius Medical Care AG
- Fresenius Medical Care highlights new renal research and innovation at ERA Congress 2026
- SEC Form 6-K filed by Fresenius Medical Care AG
- Fresenius Medical Care announces new share buyback program with a total volume of around EUR 1 billion with phased execution over 12 months
- Fresenius Medical Care Annual General Meeting: Strengthening performance and advancing innovation in kidney care
- Fresenius Medical Care Reappoints Chief Financial Officer Martin Fischer
- SEC Form 6-K filed by Fresenius Medical Care AG